North America Emerges as the Hub of Oncology Precision Medicine

Precision Medicine approaches in Oncology

Cancer is recognized as one of the deadliest diseases due to the high prevalence and mortality rates across the globe. According to the World Health Organization, in the year 2020, the global cancer burden was estimated to be 20 million new cases and 10 million deaths, annually, and is anticipated to rise by nearly 60%, by 2040. The key factors contributing to the growing prevalence and pathogenesis of cancer include alcohol intake, obesity, viral infections, radiation and chemical exposure.

Currently, there are several conventional approaches, including surgery, radiation therapy, and chemotherapy that are used for the treatment of cancer. In addition, there are several nonconventional or complementary therapeutic methods that are being employed in cancer treatment, such as hormone therapy, immunotherapy and nanotherapy. However, these approaches have been found to be insufficient for dealing with intrinsic carcinogenic genetic abnormalities, which can arise from patient-specific mutations in oncogenes, tumor suppressor genes and DNA repair genes.

To address the limitations of existing treatment options, the concept of precision medicine, often known as personalized medicine, has emerged as a possible solution, which utilizes genomic knowledge to develop gene-targeted therapeutics. The development process of precision medicine involves the study of tumor features, genetic data, lifestyle of patients and environmental effects to provide tailored medicines, which hold significant potential in treating oncological disorders by shifting away from a one-size-fits-all approach. Individuals with a family history of certain types of cancer are more likely to be at risk of inheriting the condition. In such cases, precision oncology aids individuals to take genetic testing and become aware of the associated risk. Further, prior screening for cancer can help in detection of the disease at an early stage, providing a much better chance of successful treatment.

It is worth highlighting that there are number of existing precision cancer centers, such as MD Anderson Cancer CenterMemorial Sloan Kettering Cancer Center in New York and Mayo Clinic, that offer advanced technologies and treatments that are suitable for patients with rare or difficult-to-treat cancers.

Further, oncology precision medicines have shown high efficiency during clinical trials due to which the participation of volunteers in such trials has increased. This has resulted in a higher patient pool in clinical trials, helping the researchers in better decision making for the evaluated drug or technology

It is worth noting that there has been a significant rise in the number of clinical trials evaluating precision medicines for oncology. Around 6,500 clinical trials related to precision medicine in oncology have been registered in the past six years, indicating substantial research in this domain. Among these, about 60% of these clinical trials are actively recruiting to evaluate drugs for various types of cancer targeted.

Excerpted from Global Oncology Precision Medicine Market at www.ResearchAndMarkets.com; Used by permission of www.GlobeNewswire.com

Recommended Posts